Research Site
Toronto, Ontario, Canada
NCT Number: NCT00902772
The purpose of this study is to examine the abuse potential of AZD7325.
Looking for future studies?
Notify Me18 month–55 year
All sexes
Interventional
Phase 1
Toronto, Ontario, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
mg, oral dose
mg, oral dose
Time frame: Daily during Visit 2 through 9
Time frame: Prior to each treatment period
AstraZeneca
Industry
A Single-Centre, Single-Dose, Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the AbusePotential of AZD7325 in Healthy Recreational CNS Depressant Users
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.